rs 8359 has been researched along with moclobemide in 2 studies
| Studies (rs 8359) | Trials (rs 8359) | Recent Studies (post-2010) (rs 8359) | Studies (moclobemide) | Trials (moclobemide) | Recent Studies (post-2010) (moclobemide) |
|---|---|---|---|---|---|
| 24 | 4 | 1 | 788 | 240 | 113 |
| Protein | Taxonomy | rs 8359 (IC50) | moclobemide (IC50) |
|---|---|---|---|
| Amine oxidase [flavin-containing] A | Rattus norvegicus (Norway rat) | 7.7 | |
| Amine oxidase [flavin-containing] A | Homo sapiens (human) | 4.1522 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (100.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Iwata, N; Kumagae, Y; Matsui, Y | 1 |
| Plenker, A; Püchler, K; Volz, HP | 1 |
1 trial(s) available for rs 8359 and moclobemide
| Article | Year |
|---|---|
Safety, tolerability and efficacy of the reversible monoamine oxidase inhibitor RS-8359 in early clinical trials.
Topics: Antidepressive Agents; Benzamides; Depressive Disorder; Double-Blind Method; Female; Humans; Male; Middle Aged; Moclobemide; Monoamine Oxidase Inhibitors; Nitriles; Prospective Studies; Pyrimidines | 1997 |
1 other study(ies) available for rs 8359 and moclobemide
| Article | Year |
|---|---|
Deamination of norepinephrine, dopamine, and serotonin by type A monoamine oxidase in discrete regions of the rat brain and inhibition by RS-8359.
Topics: Animals; Benzamides; Biogenic Monoamines; Brain; Cerebral Cortex; Clorgyline; Corpus Striatum; Deamination; Dopamine; Dose-Response Relationship, Drug; Hippocampus; Male; Moclobemide; Monoamine Oxidase; Monoamine Oxidase Inhibitors; Nitriles; Norepinephrine; Pyrimidines; Rats; Rats, Inbred Strains; Selegiline; Serotonin | 1991 |